Image Place holder

Nancy Gillis Johnson, PharmD, PhD

Academic Rank: Assistant Member

Overview


Discipline

    • Malignant Hematology
    • Cancer Epidemiology
    • Cancer Epidemiology Program

Education & Training

Fellowship:

  • University of Florida, PharmD - Clinical Pharmacy
  • University of North Carolina, PhD - Pharmaceutical Sciences/Oncology Pharmacogenetics
  • Moffitt Cancer Center, - Molecular Epidemiology of Cancer
Research

Dr. Gillis is a molecular epidemiologist with a background in pharmacogenomics and personalized medicine. Her current research focuses on elucidating the clinical significance of clonal hematopoiesis, a pre-leukemic condition, in patients with cancer. A goal of her research program is to quantify clonal hematopoiesis as a risk factor and identify interventions or management strategies that can be translated to clinic to improve patient outcomes.    

Publications

  • Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 Jan.37(1):7-11. Pubmedid: 30403571. Pmcid: PMC6354773.
  • Coombs CC, Gillis NK, Tan X, Berg JS, Ball MC, Balasis ME, Montgomery ND, Bolton K, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp S, Levine R, Papaemmanuil E, Zehir A, Hayes DN, Padron E. Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clin Cancer Res. 2018 Dec.24(23):5918-5924. Pubmedid: 29866652. Pmcid: PMC6812550.
  • Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use. Pharmacotherapy. 2017 Sep;37(9):1043-1051. Pubmedid: 28235141.
  • Gillis NK, Padron E. Chipping in on clonal hematopoiesis. Oncotarget. 2017 Oct.8(49):84637-84638. Pubmedid: 29156670. Pmcid: PMC5689560.
  • Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan;18(1):112-121. Pubmedid: 27927582.
  • Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017 Feb;22(2):144-151. Pubmedid: 28179575. Pmcid: PMC5330702.
  • Gillis NK, Rotroff DM, Mesa TE, Yao J, Chen Z, Carulli MA, Yoder SJ, Walko CM, Teer JK, McLeod HL. Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. Oncotarget. 2017 Dec.8(70):115114-115127. Pubmedid: 29383146. Pmcid: PMC5777758.
  • Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. J Invest Dermatol. 2017 09;137(9):2021-2023. Pubmedid: 28549953.
  • Gillis NK, McLeod HL. The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat. 2016 Sep;28:28-42. Pubmedid: 27620953. Pmcid: PMC5022787.
  • Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther. 2014 Mar.95(3):269-280. Pubmedid: 24136381. Pmcid: PMC4128332.
  • Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther. 2014 Dec.96(6):655-657. Pubmedid: 25399714.
  • McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, Shahin MH, Buford TW, El Rouby NM, Sá AC, Langaee TY, Gums JG, Chapman AB, Cooper-DeHoff RM, Turner ST, Gong Y, Johnson JA. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013 Oct.8(10):e76984. Pubmedid: 24116192. Pmcid: PMC3792156.
  • Gillis NK, Zhu HJ, Markowitz JS. An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatr Dis Treat. 2011 Aug.7:501-505. Pubmedid: 21931492. Pmcid: PMC3173033.